Footnotes

National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007

[1]        Submission 4, p.1 (DoHA).

[2]        Explanatory Memorandum, p.1.

[3]        Since August 2005, a 12.5 per cent reduction has been required when the first new brand of a drug is listed on the PBS.

[4]        Submission 4, pp.13-14 (DoHA).

[5]        Submission 4, pp.19-20 (DoHA).

[6]        Second Reading Speech, p.8.

[7]        An estimated further 33 millions prescriptions for PBS listed drugs were dispensed at a cost less than the general patient co-payment and so do not appear in official PBS statistics as their entire cost was met by the patient.

[8]        Submission 4, p.3 (DoHA).

[9]        Submission 4, p.6 (DoHA).

[10]      Submission 4, pp.5-6 (DoHA).

[11]      Submission 4, p.7 (DoHA).

[12]      Second Reading Speech, p.3.

[13]      Second Reading Speech, p.2.

[14]      Submission 2, p.1 (AMA).

[15]      Submission 7, pp.1-2 (Pharmacy Guild of Australia).

[16]      Submission 6. p.3 (Medicines Australia).

[17]      Submission 5, p.2 (GMiA).

[18]      Committee Hansard 15.6.07, p.46 (DoHA).

[19]      Committee Hansard 15.6.07, p.46 (DoHA).

[20]      Committee Hansard 15.6.07, p.7 (Dr T Faunce).

[21]      Submission 1, p.14 (Dr T Faunce).

[22]      Committee Hansard 15.6.07, p.6 (Dr T Faunce).

[23]      Submission 1, p.5 (Dr T Faunce).

[24]      Submission 5, pp.2-3 (GMiA).

[25]      Submission 5, p.3 (GMiA).

[26]      Committee Hansard 15.6.07, p.42 (DoHA).

[27]      Committee Hansard 15.6.07, pp.42-43 (DoHA); see also Committee Hansard 15.6.07, pp.49-50 (DoHA).

[28]      Committee Hansard 15.6.07, p.52 (DoHA).

[29]      Committee Hansard 15.6.07, p.51 (DoHA).

[30]      Committee Hansard 15.6.07, p.52 (DoHA).

[31]      Submission 5, p.4 (GMiA).

[32]      Submission 5, pp.5-6 (GMiA).

[33]      Committee Hansard 15.6.07, p.47 (DoHA).

[34]      Committee Hansard 15.6.07, p.24 (GMiA); see also Committee Hansard 15.6.07, p.26 (GMiA).

[35]      Submission 5, p.6 (GMiA).

[36]      Committee Hansard 15.6.07, p.7 (Dr T Faunce).

[37]      Committee Hansard 15.6.07, p.37 (Medicines Australia).

[38]      Committee Hansard 15.6.07, p.43 (DoHA).

[39]      Submission 9, p.2 (CHF).

[40]      Submission 5, p.4 (GMiA).

[41]      Submission 5, p.2 (GMiA).

[42]      Submission 5, p.2 (GMiA).

[43]      Committee Hansard 15.6.07, p.9 (Dr K Harvey).

[44]      Committee Hansard 15.6.07, p.48 (DoHA).

[45]      Submission 6, p.5 (Medicines Australia).

[46]      Submission 6, pp.6-7 (Medicines Australia).

[47]      Committee Hansard 15.6.07, p.43 (DoHA).

[48]      Submission 6, p.8 (Medicines Australia).

[49]      Submission 6, pp.8-14 (Medicines Australia).

[50]      Submission 5, p.4 (GMiA).

[51]      Submission 9, p.2 (CHF).

[52]      Committee Hansard 15.6.07. pp.43-44 (DoHA).

[53]      Submission 8, p.1 (Amgen Australia).

[54]      Submission 6, pp.14-15 (Medicines Australia).

[55]      Committee Hansard 15.6.07, pp.44-45 (DoHA).

[56]      Submission 5, p.6 (GMiA).

[57]      Committee Hansard 15.6.07, pp.45-46 (DoHA).

[58]      Submission 2, p.2 (AMA).

[59]      Submission 9, p.2 (CHF).

[60]      Submission 9, p.2 (CHF).